Biocon rises as its arm gets voluntary action indicated classification for Bengaluru facility
Biocon is currently trading at Rs. 400.65, up by 2.10 points or 0.53% from its previous closing of Rs. 398.55 on the BSE.
The scrip opened at Rs. 398.95 and has touched a high and low of Rs. 403.55 and Rs. 398.00 respectively. So far 45836 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 403.55 and Rs. 390.90 respectively. The current market cap of the company is Rs. 53364.90 crore.
The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.71% and 16.83% respectively.
U.S. Food and Drug Administration (USFDA) CDER-OC, Office of Manufacturing Quality has classified Biocon’s subsidiary -- Biocon Biologics’ (BBL) Drug Substance facility at Biocon Campus, located in Bengaluru, Karnataka, as Voluntary Action Indicated (VAI).
This relates to the inspection conducted by the agency between August 26 to September 3, 2025, and pertains to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States. Biocon Biologics remains committed to global standards of Quality and Compliance.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
